Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics, Inc.

Analysts see a few thematic ETFs that stand out this August for investors seeking long‑run growth in digital assets and healthcare. These include t...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APGE	$134.84	+0.26%	1.50M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APGE	$134.84	+0.3%	1.50M
3
4
5
6

APGE

APGE

Get Apogee Therapeutics, Inc. Data in Excel

Get Apogee Therapeutics, Inc. Data in Excel